Reports

Drug name	NICE TAs	Comments
Ribociclib (Kisqali®)	TA496 - Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer TA593 - Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer TA687 - Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer	For hospital use only
Ribociclib (Kisqali®)	NICE TA 1086 Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence
Riluzole tablets	TA20 - Guidance on the use of Riluzone (Rilutek) for the treatment of Motor Neurone Disease	ESCA
Rimegepant	TA906 - Rimegepant for preventing migraine TA919 - Rimegepant for treating migraine
Risankivzub (Skyrizi®)	TA596 - Risankizumab for treating moderate to severe plaque psoriasis
Risankizumab (Skyrizi®)	TA998: Risankizumab for treating moderately to severely active ulcerative colitis
Risdiplam (Evrysdi®)	TA755 - Risdiplam for treating spinal muscular atrophy
Ritlecitinib	TA958 - Ritlecitinib for treating severe alopecia areata in people 12 years and over
Ritumixab infusion (Mabthera®, Truxima®)	TA195 - Drugs for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Rituximab	TA243 - Rituximab for the first-line treatment of stage III-IV follicular lymphoma TA193 - Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia TA174 - Rituximab for the first-line treatment of chronic lymphocytic leukaemia TA137 - Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma TA65 - Rituximab for aggressive non-Hodgkin's lymphoma TA195 - Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor TA308 - Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis TA226 - Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports